Related Experiment Video
Updated: May 6, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Reduced expression of PDLIM4 gene correlates with good prognosis in acute myeloid leukemia
1Department of Hematology, Central Laboratory, Jiangsu University People's Hospital, Zhenjiang 212002, Jiangsu Province, China.
Abstract:
This study was aimed to investigate the expression pattern of gene PDLIM4 (PDZ and LIM domain 4) and analyze its clinical correlation with the patients suffered from acute myeloid leukemia (AML). The expression pattern of PDLIM4 in AML was detected by using EvaGreen real-time quantitative PCR (RQ-PCR). The results showed that the PDLIM4 transcript significantly decreased in 94 AML patients, compared with 21 controls (P < 0.01). The decrease of PDLIM4 transcript was found in 42 (45%) AML patients. PDLIM4 low-expression occurred among the subtypes of M1/M2/M3 more frequently than that in M4/M5/M6 (56% vs 20%, P < 0.01). AML patients with PDLIM4 low-expression had an overall survival (OS) higher than that in AML patients without PDLIM4 low-expression (P < 0.05). Analysis with receiver operating characteristic curve (ROC) displayed that PDLIM4 expression possesses the diagnostic value to differentiate AML from controls, with ROC curve area of 0.865 (95% CI: 0.801-0.930). It is concluded that reduced PDLIM4 expression is a common and favorable event for the good prognosis in AML, and can be used as a potential diagnostic biomarker of cancer.
Insights
Reduced expression of the PDLIM4 gene is common in acute myeloid leukemia (AML) and indicates a favorable prognosis. PDLIM4 may serve as a diagnostic biomarker for AML.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- Understanding gene expression patterns is crucial for diagnosing and predicting prognosis in AML.
- PDLIM4 (PDZ and LIM domain 4) function in cancer is not fully elucidated.
Purpose of the Study:
- To investigate the expression of PDLIM4 in AML patients.
- To analyze the correlation between PDLIM4 expression and clinical parameters in AML.
- To evaluate PDLIM4 as a potential diagnostic biomarker for AML.
Main Methods:
- Gene expression analysis using EvaGreen real-time quantitative PCR (RQ-PCR).
- Comparison of PDLIM4 transcript levels between 94 AML patients and 21 healthy controls.
- Statistical analysis including survival analysis and Receiver Operating Characteristic (ROC) curve analysis.
Main Results:
- PDLIM4 transcript levels were significantly decreased in AML patients compared to controls (P < 0.01).
- Reduced PDLIM4 expression was observed in 45% of AML patients and was more frequent in subtypes M1/M2/M3.
- Low PDLIM4 expression correlated with higher overall survival (OS) in AML patients (P < 0.05).
- ROC curve analysis indicated PDLIM4 expression has diagnostic value for AML (Area = 0.865).
Conclusions:
- Reduced PDLIM4 expression is a frequent event in AML and is associated with a favorable prognosis.
- PDLIM4 serves as a potential diagnostic biomarker for distinguishing AML from healthy individuals.
- Further research into PDLIM4's role could offer new therapeutic strategies for AML.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
08:37Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
